Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)

Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chinese medical journal 2022-08, Vol.135 (16), p.1894-1912
Hauptverfasser: Deng, Jiaojiao, Hua, Lingyang, Bian, Liuguan, Chen, Hong, Chen, Ligang, Cheng, Hongwei, Dou, Changwu, Geng, Dangmurenjiapu, Hong, Tao, Ji, Hongming, Jiang, Yugang, Lan, Qing, Li, Gang, Liu, Zhixiong, Qi, Songtao, Qu, Yan, Shi, Songsheng, Sun, Xiaochuan, Wang, Haijun, You, Yongping, Yu, Hualin, Yue, Shuyuan, Zhang, Jianming, Zhang, Xiaohua, Wang, Shuo, Mao, Ying, Zhong, Ping, Gong, Ye
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients. Practice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234.
ISSN:0366-6999
2542-5641
2542-5641
DOI:10.1097/CM9.0000000000002391